In stunning reversal, FDA clears Sarepta DMD drug it rejected 4 months ago

This post was originally published on this site

The FDA granted accelerated approval to Sarepta Therapeutics Vyondys 53 (golodirsen), a Duchenne muscular dystrophy drug it turned down just four months ago for safety reasons. (Pixabay). Share Facebook Twitter LinkedIn Email Print. The FDA’s attitude …

Click here to read full article